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The protozoan parasites Trypanosoma cruzi, Trypano-
soma brucei and Leishmania spp. are the causative
agents of the human infections Chagas’ disease, sleep-
ing sickness and leishmaniasis, respectively. These dis-
eases are responsible for more than 120 000 fatalities
annually and the loss of over 4 600 000 disease-
adjusted life-years [1]. Some of the poorest areas of the
world are afﬂicted by these vector-borne parasites, and
the accompanying economic burden is a major obsta-
cle to improving human health [2]. Current treatments
for protozoan diseases suffer from a range of prob-
lems, including severe toxic side effects [3] and
acquired drug resistance [4,5]. To compound these dif-
ﬁculties, many of the current chemotherapeutic treat-
ments require lengthy periods of hospitalization and
are prohibitively expensive [1]. Therefore, novel drug
targets and more effective drug treatments are required
to combat these problems.
Metabolic pathways that are absent from, or signiﬁ-
cantly different to, host pathways are logical starting
points for drug discovery [2,6]. Trypanosomatids are
uniquely dependent upon trypanothione [N
1N
8-
bis(glutathionyl)spermidine] as their principal thiol,
in contrast to most other organisms (including their
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The glyoxalase system, comprising the metalloenzymes glyoxalase I
(GLO1) and glyoxalase II (GLO2), is an almost universal metabolic path-
way involved in the detoxiﬁcation of the glycolytic byproduct methylglyox-
al to d-lactate. In contrast to the situation with the trypanosomatid
parasites Leishmania major and Trypanosoma cruzi, this trypanothione-
dependent pathway is less well understood in the African trypanosome,
Trypanosoma brucei. Although this organism possesses a functional GLO2,
no apparent GLO1 gene could be identiﬁed in the T. brucei genome. The
absence of GLO1 in T. brucei was conﬁrmed by the lack of GLO1 activity
in whole cell extracts, failure to detect a GLO1-like protein on immuno-
blots of cell lysates, and lack of d-lactate formation from methylglyoxal as
compared to L. major and T. cruzi. T. brucei procyclics were found to be
2.4-fold and 5.7-fold more sensitive to methylglyoxal toxicity than T. cruzi
and L. major, respectively. T. brucei also proved to be the least adept of
the ‘Tritryp’ parasites in metabolizing methylglyoxal, producing l-lactate
rather than d-lactate. Restoration of a functional glyoxalase system by
expression of T. cruzi GLO1 in T. brucei resulted in increased resistance to
methylglyoxal and increased conversion of methylglyoxal to d-lactate, dem-
onstrating that GLO2 is functional in vivo. Procyclic forms of T. brucei
possess NADPH-dependent methylglyoxal reductase and NAD
+-dependent
l-lactaldehyde dehydrogenase activities sufﬁcient to account for all of the
methylglyoxal metabolized by these cells. We propose that the predominant
mechanism for methylglyoxal detoxiﬁcation in the African trypanosome is
via the methylglyoxal reductase pathway to l-lactate.
Abbreviations
GLO1, glyoxalase I; GLO2, glyoxalase II; TcGLO1, Trypanosoma cruzi glyoxalase I.
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amyl-l-cysteinylglycine) [7]. This dithiol is primarily
responsible for the maintenance of thiol-redox homeo-
stasis within trypanosomatids, and is crucially involved
in the protection of parasites from oxidative stress [8],
heavy metals [9] and xenobiotics [10]. Several enzymes
involved in trypanothione biosynthesis and its down-
stream metabolism have been genetically and chemi-
cally validated as essential for parasite survival [11].
Consequently, trypanothione-dependent enzymes have
become the focus of much anti-trypanosomatid drug
discovery.
The glyoxalase system, comprising the metallo-
enzymes glyoxalase I (GLO1, EC 4.4.1.5) and glyoxa-
lase II (GLO2, EC 3.1.2.6), together with glutathione
as cofactor, is a widely distributed pathway involved
in metabolism of the toxic and mutagenic glycolytic
byproduct methylglyoxal [12,13]. A unique trypanothi-
one-dependent glyoxalase system has been identiﬁed in
Leishmania spp. and T. cruzi [14–16]. In the ﬁrst step,
GLO1 isomerizes the spontaneous hemithioacetal
adduct formed between trypanothione and methylgly-
oxal to S-d-lactoyltrypanothione [14]. In the second
step, GLO2 catalyses hydrolysis of this ester, releasing
d-lactate and regenerating trypanothione. The trypano-
thione-dependent glyoxalase system in these parasites
differs signiﬁcantly from that employed by their mam-
malian hosts, which depends entirely on glutathione as
a thiol cofactor. These differences in substrate speciﬁc-
ity may provide an opportunity for the speciﬁc
chemotherapeutic targeting of these enzymes in the try-
panosomatids. As inhibitors of the glyoxalase system
have already been shown to possess both anticancer
[17] and antimalarial [18] activities, it is possible that
inhibition of the trypanothione-dependent glyoxalase
pathway may prove toxic to trypanosomatids.
Although glyoxalase metabolism has been well
deﬁned in both Leishmania major and T. cruzi, this
pathway is less well understood in T. brucei. Intrigu-
ingly, the recently completed T. brucei genome
revealed that although this organism possesses a func-
tional GLO2 [19], no apparent GLO1 gene or homo-
logue could be identiﬁed [20]. This was unexpected, as
the bloodstream form of T. brucei has an extremely
high glycolytic ﬂux and relies solely on substrate-level
phosphorylation for ATP production [21]. Triose phos-
phates are a major source of methylglyoxal [12,13],
and thus the reported antiproliferative effects of exoge-
nous dihydroxyacetone [22] or endogenous modulation
of triose phosphate isomerase in T. brucei [23] could
be due to methylglyoxal toxicity. Should the absence
of GLO1 from this pathogen be conﬁrmed, it may
have important implications for the viability of the
glyoxalase system as a target for antitrypanosomatid
chemotherapy. In this study, we attempted to further
characterize the unusual methylglyoxal metabolism of
T. brucei and directly compare it to that of T. cruzi
and L. major.
Results and Discussion
Analysis of methylglyoxal-catabolizing enzymes
in trypanosomatid cell extracts
Sequencing of the ‘Tritryp’ genomes has revealed
several interesting distinctions between the cellular
metabolism of T. brucei, T. cruzi and L. major [20]. In
our current study, we sought to examine the apparent
absence of a gene encoding a GLO1 homologue from
the T. brucei genome, GLO1 being a ubiquitous
enzyme required for the metabolism of methylglyoxal.
Initially, the relative activities of enzymes involved in
methylglyoxal metabolism were compared in these
medically signiﬁcant trypanosomatids. Whole cell
extracts of T. cruzi epimastigotes, L. major promastig-
otes and T. brucei (bloodstream and procyclic forms)
were prepared, and the activities of methylglyoxal-
catabolizing enzymes were determined (Table 1). In
keeping with previously published data [14,15], trypa-
nothione-dependent GLO1 activity was detected in
both L. major and T. cruzi extracts with speciﬁc activi-
ties of 85 and 42 nmolÆmin
)1Æmg
)1, respectively. How-
ever, GLO1 activity could not be detected in extracts
of T. brucei procyclic or bloodstream forms, with
either trypanothione or glutathione hemithioacetals as
substrate. In contrast, trypanothione-dependent GLO2
activity was detected in all cell lysates. With S-d-lacto-
yltrypanothione as a substrate, L. major extracts dem-
onstrated GLO2 activity of 62.8 nmolÆmin
)1Æmg
)1,
over sixfold higher than that of T. cruzi extracts
(8.8 nmolÆmin
)1Æmg
)1). Despite the apparent lack of
GLO1 activity, both T. brucei bloodstream form and
procyclic extracts effectively metabolized S-d-lacto-
yltrypanothione, with speciﬁc activities of 18 and
23 nmolÆmin
)1Æmg
)1, respectively. Trypanothione
reductase activities were also assayed in each lysate to
ensure adequate extraction of the parasites, and were
in line with previously published data [24].
Western blot analyses of cell extracts
To conﬁrm the absence of GLO1 from T. brucei at the
protein level, immunoblots of trypanosomatid whole
cell lysates were probed with L. major GLO1-speciﬁc
polyclonal antiserum (Fig. 1). As expected, a protein
of 16 kDa, which is equivalent to the predicted molec-
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serum in both the L. major and the T. cruzi lysates.
No GLO1-like protein was detected in whole cell
lysates of T. brucei procyclics, despite overexposure of
the blot. In combination with our enzymatic analysis
of cell extracts, these data conﬁrm the absence of a
functional GLO1 enzyme within T. brucei. This situa-
tion is not entirely without precedence. Cestode and
digenean parasitic helminths have been studied that
lack GLO1 while maintaining high levels of GLO2
activity [25]. One explanation for the retention of this
enzyme is that T. brucei GLO2 has methylglyoxal-inde-
pendent functions. Indeed, human GLO2 has demon-
strated substrate promiscuity in efﬁciently hydrolysing
thiol esters of simple acids such as formic acid, succi-
nic acid and mandelic acid [13]. The identiﬁcation of
the true physiological substrate of T. brucei GLO2 will
form the basis of our future studies.
Effects of methylglyoxal on trypanosomatid
growth
The absence of GLO1 from T. brucei suggested that
these parasites may be particularly susceptible to the
toxic effects of methylglyoxal. With this in mind, T. cru-
zi, L. major and T. brucei were grown in the presence of
increasing methylglyoxal concentrations, and the rela-
tive growth of each culture was determined after 72 h
(Fig. 2). To allow the direct comparison of the methyl-
glyoxal sensitivity of these parasites, each cell line was
adapted for growth in SDM-79 medium prior to analy-
sis. T. brucei procyclics were the most sensitive to meth-
ylglyoxal toxicity, with an EC50 of 70 ± 2 lm, whereas
T. cruzi epimastigotes and L. major promastigotes were
2.4-fold and 5.7-fold less sensitive, with EC50 values of
171 ± 11 and 397 ± 27 lm, respectively.
GLO1
T. cruzi L. major T. brucei
Fig. 1. Immunoblot analysis of trypanosomatid whole cell lysates.
Immunoblots of whole cell extracts (30 lg of protein in each lane)
from T. cruzi epimastigotes, L. major promastigotes and T. brucei
procyclics were probed with antiserum to L. major GLO1.
Table 1. Analysis of methylglyoxal-catabolizing activities in trypanosomatid lysates. All enzymatic activities were assayed as described in
Experimental procedures, and corrected for nonenzymatic background rates. Speciﬁc activities represent the means ± SD of six determina-
tions from two independent experiments.
Enzyme
Speciﬁc activity (nmolÆmin
)1Æmg
)1)
L. major T. cruzi T. brucei procyclics
T. brucei bloodstream
forms
GLOI 85.1 ± 3.8 42.3 ± 2.4 < 5 < 5
GLOII 62.8 ± 3.6 8.82 ± 0.29 17.9 ± 2.1 22.9 ± 3.4
Methylglyoxal reductase 5.3 ± 0.7 4.8 ± 0.42 9.4 ± 1.1 10 ± 2.3
Lactaldehyde dehydrogenase 0.51 ± 0.004 0.48 ± 0.02
a 1.24 ± 0.11 < 0.4
Trypanothione reductase 266 ± 30 133 ± 5.6 39.6 ± 2.8 46.3 ± 3.9
a Activity measured in whole cell lysate.
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Fig. 2. EC50 values for methylglyoxal against the ‘Tritryp’ trypano-
somatids. The EC50 values for methylglyoxal against L. major prom-
astigotes (open squares), T. cruzi epimastigotes (open triangles)
and T. brucei procyclics (closed circles) were determined. The
curves are the nonlinear ﬁts of data using a two-parameter EC50
0–100% equation provided by GRAFIT (see Experimental proce-
dures). EC50 values of 70 ± 2 methylglyoxal, 171 ± 11 and
397 ± 27 lM were determined for T. brucei, T. cruzi and L. major
with corresponding slope factors (m) of 3.0, 1.6 and 1.59, respec-
tively. Data are the means of triplicate measurements.
Methylglyoxal metabolism in trypanosomatids N. Greig et al.
378 FEBS Journal 276 (2009) 376–386 ª 2008 The Authors Journal compilation ª 2008 FEBSBloodstream trypanosomes could not be adapted for
growth in SDM-79 medium, and attempts to determine
the methylglyoxal sensitivity of these cells in HMI-9
medium proved unsuccessful, due to the propensity of
methylglyoxal to react with thiols in this culture med-
ium. In a previous study on the curative effect of
methylglyoxal in cancer-bearing mice [26], Ghosh et al.
established the pharmacokinetic properties of methyl-
glyoxal in blood following oral dosing. Using this
methodology, we examined the effects of methylglyoxal
on an in vivo T. brucei infection. The maximum achiev-
able methylglyoxal concentration in blood following
oral dosing of mice was 20 lm, and at this level there
was no discernible effect on the progression of the par-
asite infection (data not shown). These results suggest
that the methylglyoxal EC50 for bloodstream T. brucei
in vivo is in excess of 20 lm.
Trypanosomatid metabolism of methylglyoxal
The rate of exogenous methylglyoxal metabolism by
T. cruzi, L. major and T. brucei (bloodstream and
procyclic forms) was determined (Fig. 3). Each cell
line was resuspended in a minimal medium that had
been preincubated with 1.5 mm methylglyoxal for
90 min. At deﬁned intervals, culture supernatants were
removed and analysed for residual methylglyoxal. In
keeping with both our enzymatic analysis of whole
cell lysates and EC50 data, L. major promastigotes
dealt with exogenous methylglyoxal most efﬁciently,
with an initial rate of 67 nmolÆmin
)1ÆmL
)1. In com-
parison, T. cruzi epimastigotes were considerably
less effective at metabolizing methylglyoxal (47.6
nmolÆmin
)1ÆmL
)1). However, T. brucei procyclics and
bloodstream forms proved to be the least adept at
dealing with this toxic oxoaldehyde, metabolizing
methylglyoxal with initial rates of 7.4 nmolÆ
min
)1ÆmL
)1 and 9.8 nmolÆmin
)1ÆmL
)1, respectively.
These results suggest that although T. brucei is
predicted to be the most vulnerable of the ‘Tritryp’
trypanosomatids to methylglyoxal toxicity, it can
effectively metabolize methylglyoxal despite the
absence of a complete glyoxalase pathway.
Products of trypanosomatid metabolism of
methylglyoxal
In all studies to date, the principal product of thiol-
dependent metabolism of methylglyoxal has been
d-lactate [27–29]. Consequently, methylglyoxal-treated
parasites were monitored for the production of lactate,
using d-lactate and l-lactate dehydrogenase-based
assays (Table 2). As expected, both L. major and
T. cruzi cells produced considerable amounts of d-lac-
tate following exposure to methylglyoxal, accounting
for approximately 30% of free methylglyoxal in the
medium. In contrast, T. brucei (procyclics and blood-
stream forms) produced only trace amounts of d-lac-
tate. Instead, methylglyoxal-treated T. brucei procyclics
and bloodstream forms produced signiﬁcant quantities
of the stereoisomer l-lactate (120 and 221 lm in 2 h,
respectively). The sixfold higher rate of l-lactate pro-
duction by bloodstream parasites in the absence of
exogenous methylglyoxal reﬂects the extremely high
glycolytic rate in this developmental form of the Afri-
can trypanosome [30]. The addition of methylglyoxal
marginally decreased the amount of l-lactate detected
in the supernatants of both L. major and T. cruzi
cultures. These data suggest that T. brucei may meta-
bolize methylglyoxal by an alternative pathway.
In a previous study [31], Ghoshal et al. identiﬁed
NADPH-dependent methylglyoxal reductase activity in
Leishmania donovani promastigotes. These parasites
were shown to metabolize approximately 1.2% of the
exogenous methylglyoxal added to cultures via this
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Fig. 3. Metabolism of methylglyoxal in the ‘Tritryp’ trypanoso-
matids. The metabolism of methylglyoxal (1.5 mM) by mid-log
L. major promastigotes (open squares), T. cruzi epimastigotes
(open triangles), T. brucei procyclics (closed circles) and T. brucei
bloodstream forms (open circles) was monitored over 1 h. Methyl-
glyoxal metabolism in assay buffer in the absence of cells was
also measured (open diamonds). Data are ﬁtted to single exponen-
tial ﬁts using equations in GRAFIT, and are the means of triplicate
measurements.
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uct. In view of the generation of considerably higher
levels of l-lactate by methylglyoxal-treated T. brucei,
we hypothesized that methylglyoxal reductase activity
may be elevated in T. brucei to compensate for the
absence of GLO1. Indeed, when NADPH-dependent
methylglyoxal reductase activity was measured in all
three trypanosomatid cell lysates, a twofold higher
reductase activity was observed in T. brucei procyclic
and bloodstream extracts, respectively, than that seen
in L. major and T. cruzi cells (Table 1). If we consider
that procyclics metabolize exogenous methylglyoxal at
a rate of 7.4 nmolÆmin
)1 per 10
8 cells (Fig. 3), and
assuming that 10
8 cells is equivalent to 1 mg of protein
[32], this elevated methylglyoxal reductase activity
could conceivably account for all methylglyoxal metab-
olism in T. brucei. Although a T. brucei methylglyoxal
reductase has yet to be identiﬁed, two putative aldo-
keto reductase genes (Tb927.2.5180 and Tb11.02.3040),
whose protein products are members of the same aldo-
keto reductase superfamily as methylglyoxal reductase,
have been annotated in the genome. To date, attempts
to express these genes as soluble recombinant proteins
have proved unsuccessful. In mammalian cells, methyl-
glyoxal can also be detoxiﬁed by two methylglyoxal
dehydrogenase enzymes (oxoaldehyde dehydrogenase
and betaine aldehyde dehydrogenase) [33]. No homo-
logues of these enzymes were identiﬁed in the T. brucei
genome, and neither NAD
+-dependent nor NADP
+-
dependent methylglyoxal dehydrogenase activities were
detected in T. brucei extracts (data not shown).
To complete the metabolism of l-lactaldehyde to
lactate, T. brucei would require a functional l-lactalde-
hyde dehydrogenase. Although lactaldehyde dehydro-
genase activity has previously been detected in
L. donovani cell lysates [31], it has yet to be identiﬁed
in either T. cruzi or in T. brucei. Using l-lactaldehyde
as a substrate, l-lactaldehyde dehydrogenase activity
was measured in all three insect-stage trypanosomatid
cell lysates (Table 1), and was found to be relatively
similar in L. major and T. cruzi lysates (0.51 ± 0.004
and 0.48 ± 0.02 nmolÆmin
)1Æmg
)1, respectively). In
comparison, l-lactaldehyde dehydrogenase activity
was found to be elevated approximately 2.4-fold in
T. brucei procyclic cell lysates (1.24 ± 0.11 nmolÆ
min
)1Æmg
)1). However, activity could not be detected
in the bloodstream stage of the parasite. These studies
conﬁrm that procyclic T. brucei organisms are capable
of metabolizing methylglyoxal, via a methylglyoxal
reductase-dependent pathway, to l-lactate; however, it
remains to be seen whether this is the predominant
pathway for methylglyoxal detoxiﬁcation in these cells.
Our failure to detect NAD
+-dependent l-lactaldehyde
dehydrogenase activity in T. brucei bloodstream forms
may be due to technical reasons, such as NADH
oxidation via the glycerophosphate oxidase system
masking the formation of NADH.
Expression of T. cruzi GLO1 (TcGLO1) in T. brucei
Can T. brucei utilize a complete glyoxalase system?
To address this question, a tetracycline-inducible
pLew100–TcGLO1 construct was generated and trans-
fected into both bloodstream and procyclic cells.
Western blot analysis of transgenic parasites, following
induction with tetracycline, conﬁrmed the expression
of a 16-kDa protein that reacted strongly with GLO1-
speciﬁc antiserum (Fig. 4; bloodstream data not
shown). This protein was not evident in cells transfect-
ed with an unrelated vector (pLew100–luciferase).
Antiserum against T. brucei pteridine reductase 1 was
used to establish equal loading of samples. The expres-
sion of recombinant TcGLO1 in procyclics and blood-
stream forms was conﬁrmed when GLO1 activity
(23.0 ± 1.9 and 38.2 ± 1.9 nmolÆmin
)1Æmg
)1, respec-
tively) was detected in cell extracts. Indeed, the rate of
exogenous methylglyoxal metabolism in these trans-
genic T. brucei cell lines increased markedly, with
GLO1-expressing procyclic and bloodstream cells
metabolizing the toxic oxoaldehyde 1.7-fold and
Table 2. Comparison of methylglyoxal-stimulated D-lactate and L-lactate production by trypanosomatids. Parasites were incubated with or
without methylglyoxal for 2 h prior to analysis. Data represent the mean ± SD of triplicate determinations. See Experimental procedures for
further details.
Organism
Lactate (lM)
D-Lactate L-Lactate
Plus methylglyoxal Minus methylglyoxal Net Plus methylglyoxal Minus methylglyoxal Net
L. major 385 ± 9 49 ± 9 337 7 ± 0.6 12 ± 0.1 )5
T. cruzi 303 ± 3 8 ± 0.8 295 9 ± 0.3 13 ± 0.1 )4
T. brucei procyclics 18 ± 0.2 8 ± 0.1 11 141 ± 5 21 ± 0.1 120
T. brucei bloodstream forms 68 ± 9 50 ± 2 18 355 ± 42 134 ± 18 221
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importantly, TcGLO1-expressing T. brucei procyclics
were almost 3.5-fold less sensitive to methylglyoxal
than wild-type or luciferase-expressing cells.
To conﬁrm that enhanced methylglyoxal tolerance
in GLO1-expressing T. brucei was due to complemen-
tation of the glyoxalase system, lactate production in
the supernatants of methylglyoxal-treated wild-type
and transgenic cells was measured (Table 4). Whereas
l-lactate levels in the supernatants of GLO1-expressing
T. brucei (bloodstream forms and procyclics) were very
similar to those of the wild-type, d-lactate production
was found to be signiﬁcantly higher (  3-fold,
P < 0.0001). d-Lactate levels failed to reach those
seen in the supernatants of methylglyoxal-treated
L. major and T. cruzi, but were sufﬁcient to suggest
that GLO1 expression in T. brucei procyclic and
bloodstream parasites results in a complete glyoxalase
system.
Implications for parasite chemotherapy
Mammalian cells maintain a repertoire of four path-
ways for metabolism of methylglyoxal [33], whereas our
studies suggest that the African trypanosome may be
solely dependent upon methylglyoxal reductase (Fig. 5).
The absence of a functioning glyoxalase system within
T. brucei, recognized as the principal route of oxoalde-
hyde detoxiﬁcation in almost all cells, is especially per-
plexing. As methylglyoxal is generated primarily as a
byproduct of glycolysis, and African trypanosomes are
entirely dependent upon glycolysis for energy, it would
be reasonable to assume that T. brucei would preserve
robust methylglyoxal-metabolizing systems. Without an
GLO1
PTR1
T. brucei 
pLew100-luciferase
T. brucei 
pLew100-TcGLO1
Fig. 4. TcGLO1 expression in T. brucei procyclics. Immunoblots of
cell extracts of T. brucei procyclics transfected with either
pLew100–luciferase or pLew100–TcGLO1 were probed with antise-
rum to L. major GLO1 and T. brucei pteridine reductase 1 (PTR1)
(1 · 10
7 parasites in each lane). Cells were induced with tetra-
cycline for 24 h prior to analysis.
Table 3. Comparison of GLO1 activity, methylglyoxal sensitivity
and methylglyoxal metabolism in T. brucei wild-type and transgenic
cell lines. ND, not determined.
Cell line
GLO1 activity
(nmolÆmin
)1Æ
mg
)1)E C 50
a (lM)
Methylglyoxal
metabolized
b
(nmolÆmL
)1Æh
)1)
T. brucei
Procyclics < 5 53.4 ± 2.9 246 ± 21
Bloodstream forms < 5 ND 300 ± 32
pLew100–luciferase
c
Procyclics < 5 47.8 ± 3.8 197 ± 16
Bloodstream forms < 5 ND 260 ± 28
pLew100–TcGLO1
c
Procyclics 23.0 ± 1.9 175 ± 5.6
d 387 ± 27
Bloodstream forms 38.2 ± 1.9 ND 810 ± 40
a Values are the weighted means of three independent experi-
ments.
b All data represent the mean ± SD of six determinations
from two independent experiments.
c Cell lines were grown in the
presence of tetracycline for 24 h prior to analysis.
d P < 0.001 as
compared to T. brucei.
Table 4. Comparison of methylglyoxal-stimulated D-lactate and L-lactate production by wild-type and transgenic T. brucei cell lines. Data
represents the mean ± SD of six determinations from two independent experiments.
Cell line
Lactate (lM)
D-Lactate L-lactate
Plus methylglyoxal Minus methylglyoxal Net Plus methylglyoxal Minus methylglyoxal Net
T. brucei
Procyclics 22 ± 3 10 ± 2 12 148 ± 7 24 ± 3 124
Bloodstream forms 68 ± 9 50 ± 2 18 355 ± 42 134 ± 18 221
pLew100–luciferase
Procyclics 17 ± 2 9 ± 1 8 134 ± 12 19 ± 2 115
Bloodstream forms 59 ± 2 48 ± 3 11 329 ± 26 118 ± 21 211
pLew100–TcGLO1
Procyclics 57 ± 4
a 19 ± 2 38 122 ± 9 22 ± 2 100
Bloodstream forms 183 ± 24
a 71 ± 5 112 308 ± 14 105 ± 8 203
a P < 0.001 as compared to T. brucei.
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ticularly vulnerable to methylglyoxal toxicity, and our
current studies appear to conﬁrm this. These ﬁndings
have broad implications for the targeting of methyl-
glyoxal metabolism for antitrypanosomatid chemo-
therapy. Previous studies have suggested that the
contrasting substrate speciﬁcities of the human and
trypanosomatid glyoxalase enzymes (GLO1 and
GLO2) make them attractive targets for rational drug
design [14,15,19]. Whereas this may still be the case
in T. cruzi and Leishmania spp., methylglyoxal reduc-
tase is clearly a more promising drug target in the
African trypanosome. Identiﬁcation of the genes
that encode this enzyme in T. brucei should now be a
priority.
Experimental procedures
Cell lines and culture conditions
L. major promastigotes (Friedlin strain; WHO designation
MHOM⁄JL⁄81⁄Friedlin), procyclic trypomastigotes of
T. brucei brucei S427 29-13 and epimastigotes of T. cruzi
CL Brener (genome project standard clone) were adapted
for growth in SDM-79 medium supplemented with 10%
fetal bovine serum (Gibco, Paisley, UK) and haemin
(100 mgÆL
)1). L. major promastigotes were grown at 24  C
with shaking, and T. brucei and T. cruzi were cultured at
28  C. T. brucei bloodstream forms were cultured at 37  C
in modiﬁed HMI9 medium (56 lm 1-thioglycerol was
substituted for 200 lm 2-mercaptoethanol) supplemented
with 2.5 lgÆmL
)1 G418 to maintain expression of T7 RNA
polymerase and the tetracycline repressor protein [34].
In order to directly compare the effects of methylglyoxal
on the growth of these trypanosomatids, triplicate cultures
containing methylglyoxal were seeded at 5 · 10
5 parasites
per mL. As methylglyoxal interferes with the Alamar blue
assay for viable cells, cell densities were determined using
the CASY Model TT cell counter (Scha ¨ rfe, Renlingen,
Germany) after culture for 72 h. Concentrations of inhib-
itor causing a 50% reduction in growth (EC50) were deter-
mined using the following two-parameter equation by
nonlinear regression using grafit:
y ¼
100
1 þð ½ I =EC50Þ
m
where the experimental data were corrected for background
cell density and expressed as percentages of the uninhibited
control cell density. In this equation, [I] represents inhibitor
concentration, and m is the slope factor.
Analysis of methylglyoxal-catabolizing enzymes
in trypanosomatid cell lysates
L. major promastigotes (2 · 10
7 mL
)1, 1 L), T. cruzi epim-
astigotes (3 · 10
7 mL
)1, 1 L) and T. brucei brucei procyclics
(2 · 10
7 mL
)1, 1 L) were pelleted by centrifugation (1600 g,
10 min, 4  C), washed twice in 20 mm Tris (pH 7.0) con-
taining 0.1 mm sucrose, and resuspended in cell lysis buffer
(10 mm potassium phosphate, pH 7.0). For biological
safety, parasites were inactivated by three cycles of freezing
and thawing, before lysis under pressure (30 kpsi) using a
one-shot cell disruptor (Constant Systems, Daventry, UK).
T. brucei bloodstream forms (4 · 10
9 cells), harvested from
rats as previously described [35], were lysed using an
alternative method. Cells were pelleted by centrifugation
Fig. 5. Metabolism of methylglyoxal. In
T. cruzi and L. major, the principal end-prod-
uct of methylglyoxal metabolism is D-lactate.
In the absence of GLO1, T. brucei does not
maintain an intact glyoxalase system, and
may metabolize methylglyoxal via methylgly-
oxal reductase (MeGR) and lactaldehyde
dehydrogenase (LADH) to L-lactate. Solid
lines: conﬁrmed metabolism in T. brucei.
Dotted lines: metabolism absent in T. bru-
cei. MeGDH, methylglyoxal dehydrogenase;
LDH, lactate dehydrogenase.
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pH 8.0, 1.5% (w⁄v) glucose and 0.5 mgÆmL
)1 BSA], resus-
pended in ice-cold de-ionized dH2O, (500 lL) and vortexed.
Lysed bloodstream trypanosomes were then incubated on
ice for 10 min prior to the addition of 2· lysis buffer
(500 lL) and further vortexing. From this point, all lysates
were treated in an identical manner. Following centrifuga-
tion (800 g, 20 min, 4  C), cell supernatants were collected
and dialysed against 50 mm Hepes (pH 7.0) with 25 mm
NaCl and 150 lm 2-mercaptoethanol at 4  C to remove
components of less than 3.5 kDa. The protein concentra-
tion of each lysate was determined using Bradford reagent
(Bio-Rad, Hemel Hempstead, UK). GLO1 activity in the
trypanosomatid cell lysates was measured by monitoring
the formation of S-d-lactoyltrypanothione spectrophoto-
metrically at 240 nm [14]. Trypanothione and methylglyoxal
were preincubated at 25  C for 10 min in 50 mm Hepes
(pH 7.0) plus 25 mm NaCl, 50 lm adduct, and 100 lm free
thiol. Reactions were initiated with enzyme extract. Methyl-
glyoxal reductase and GLO2 activities were determined as
previously described [14,31,36]. The activity of trypano-
thione reductase, used as a control enzyme, was assayed as
previously described [37].
L-Lactaldehyde dehydrogenase activity in
trypanosomatids
l-Lactaldehyde, the substrate of l-lactaldehyde dehydroge-
nase, was prepared from d-threonine, as previously
described [38]. Brieﬂy, 25 mmol of d-threonine, 9.1 g of nin-
hydrin and 600 mL of 0.05 m sodium citrate buffer (pH 5.4)
were combined and boiled for 15 min with continual stir-
ring. After being cooled to room temperature, the mixture
was ﬁltered and treated with sufﬁcient Dowex 1-X8 resin
(bicarbonate form) to raise the pH to 6.5. After stirring for
a further 2–3 h, the resin was again ﬁltered, and the ﬁltrate
was adjusted to pH 4.0 by the addition of Dowex 50 resin
(hydrogen ion form). Following ﬁltration, the ﬁltrate was
concentrated down to 50–100 mL using a rotary evaporator.
The resulting concentrate was then sequentially treated with
Dowex 1-X8 and Dowex 50 resins, as previously described,
and further concentrated to 20–30 mL. Dowex 1-X8 resin
was then added to the concentrated ﬁltrate in batches until
the solution was colourless, and the pH was adjusted to 7.5.
The l-lactaldehyde yield from this reaction was determined
by monitoring NADH production at 340 nm following
incubation with aldehyde dehydrogenase from baker’s yeast
(Fluka, Gillingham, UK). Reactions were performed in
100 mm Tris⁄HCl (pH 8.5), 3 mm NAD
+ and 10 units of
aldehyde dehydrogenase. The purity of the synthetic
l-lactaldehyde was analysed by liquid chromatography–MS.
Samples were derivatized with excess 2,4-dinitrophenyl-
hydrazine (Fluka) in 5 mm HCl, diluted with acetonitrile⁄
water (1 : 1), and analysed by liquid chromatography–
MS (Phenomenex Gemini C18 column, 50 · 3.0 mm, 5 lm
particle size; mobile phase, water⁄acetonitrile + 0.1%
HCOOH 80 : 20 to 5 : 95 over 3.5 min, and then held for
1.5 min; ﬂow rate 0.5 mLÆmin
)1). LC-MS analysis detected
the expected lactaldehyde hydrazone plus an additional
hydrazone (the contaminant was not present in the unde-
rivatized l-lactaldehyde preparation, or the 2,4-dinitro-
phenylhydrazine reagent). The mass and retention time of
the contaminating hydrazone was consistent with the
impurity in the l-lactaldehyde preparation being acetone or
propionaldehyde (as shown by comparison with the hydra-
zones of acetone and propionaldehyde synthesized as
described above). Biochemical assays on L. major cell-free
extracts indicated that neither acetone nor propionaldehyde
was responsible for the observed activity.
l-Lactaldehyde dehydrogenase activity was measured in
soluble trypanosomatid extracts, prepared as above, except
that a further centrifugation (100 000 g, 1 h, 4  C) and dial-
ysis step was introduced prior to analysis. Activity was
measured at 27  C in 100 mm Tris⁄HCl (pH 8.5) with
3m m NAD
+ and 1 mml -lactaldehyde [39]. Trypanosoma-
tid extracts were incubated with NAD
+ at 27  C for 5 min,
prior to the initiation of the reaction with l-lactaldehyde.
Reactions were monitored at 340 nm for the formation of
NADH.
Western blot analyses of trypanosomatid cell
extracts
Polyclonal antisera against L. major GLO1 were raised in
adult male Wistar rats. An initial injection of 100 lgo f
puriﬁed antigen, emulsiﬁed in complete Freund’s adjuvant,
was followed by two identical booster injections of antigen
emulsiﬁed in Freund’s incomplete adjuvant at 2 week
intervals.
Trypanosomatid whole cell extracts (30 lg) were sepa-
rated by SDS⁄PAGE and subsequently transferred onto
nitrocellulose. After blocking with 7% skimmed milk in
NaCl⁄Pi for 1 h, blots were incubated with L. major GLO1
polyclonal antiserum (1 : 700 dilution) for 1 h, washed in
NaCl⁄Pi containing 0.1% (v⁄v) Tween-20, and then incu-
bated with a secondary antibody [rabbit anti-(rat IgG)]
(Dako, Ely, UK; 1 : 10 000 dilution). Immunoblots were
developed using the ECL plus (enhanced chemiluminescence)
system from Amersham Biosciences (Piscataway, NJ, USA).
Analysis of methylglyoxal metabolism in
trypanosomatids
Mid-log L. major promastigotes, T. cruzi epimastigotes
and T. brucei procyclics (4 · 10
8 cells) were pelleted by
centrifugation (1600 g, 10 min, 4  C) and washed in a
maintenance medium (250 mm sucrose, 25 mm Tris,
pH 7.4, 1 mm EDTA, 8 gÆL
)1 glucose, and 0.5 mgÆmL
)1
BSA). Cells were then resuspended at 1 · 10
8 mL
)1 in
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1.5 mm methylglyoxal for 90 min prior to resuspension. In
the case of T. brucei bloodstream forms, cells were pel-
leted by centrifugation (800 g, 10 min, 4  C), and washed
in PSG buffer with 0.5 mgÆmL
)1 BSA. Bloodstream try-
panosomes were then resuspended at 1 · 10
8 mL
)1 in PSG
buffer with 0.5 mgÆmL
)1 BSA that had been preincubated
with 1.5 mm methylglyoxal for 90 min prior to resuspen-
sion. In all cases, cell viability was monitored by visibly
checking motility throughout the experiment. Metabolism
of methylglyoxal by these cells was determined by measur-
ing the methylglyoxal concentration in cell-free assay
buffer. At deﬁned intervals, aliquots were removed, cells
were pelleted at 16 000 g for 5 min, and the supernatants
were analysed for residual methylglyoxal by the semicar-
bizide assay [14].
The production of lactate by methylglyoxal-treated
mid-log L. major promastigotes, T. cruzi epimastigotes and
both T. brucei procyclic and bloodstream trypanosomes
(2 · 10
8 cells) was determined. Cells were incubated with
1.5 mm methylglyoxal in an identical manner to that previ-
ously described for the methylglyoxal metabolism studies.
Following a 2 h incubation, cells were pelleted (16 000 g,
5 min), and supernatants were assayed without further
treatment by the addition of either d-lactaldehyde dehydro-
genase or l-lactaldehyde dehydrogenase, as per the
manufacturer’s instructions. The amount of NADH formed
was measured at 340 nm, and the limit of detection for
these assays was determined to be 1 lm.
Cloning and expression of recombinant TcGLO1
in T. brucei
The T. cruzi GLO1 gene (Tc00.1047053510659.240) was
ampliﬁed by PCR from genomic DNA using the sense pri-
mer 5¢-AAGCTTATGTCAACACGACGACTTATGCAC
A-3¢ and the antisense primer 5¢-GGATCCGGATCCTT
AAGCCGTTCCCTGTTC-3¢ with additional HindIII and
BamHI restriction sites (italicised), respectively. The PCR
product was then cloned into pCR-Blunt II-TOPO (Invitro-
gen) and sequenced. The pCR-Blunt II-TOPO–TcGLO1
construct was then digested with HindIII and BamHI, and
the fragment was ligated into the tetracycline-inducible
expression vector pLew100 [40], resulting in a pLew100–
TcGLO1 construct.
T. brucei brucei procyclics [40], modiﬁed to express both
T7 polymerase and the tetracycline repressor protein, were
transfected with either pLew100–TcGLO1 or the control
vector pLew100–luciferase, as previously described [41]. Fol-
lowing transfection, cells were grown in SDM-79 medium in
the presence of 50 lgÆmL
)1 hygromycin, 15 lgÆmL
)1 genta-
micin and 2.5 lgÆmL
)1 phleomycin. T. brucei bloodstream
forms were also transfected with the pLew100–TcGLO1
vector or the pLew100–luciferase vector, as previously
described [41,42], and subsequently cultured in HMI9
medium supplemented with 2.5 lgÆmL
)1 G418, to maintain
expression of T7 RNA polymerase and the tetracycline
repressor protein, and 2.5 lgÆmL
)1 phleomycin. Methylgly-
oxal metabolism in the transfected cell lines was analysed,
as previously described, following induction of recombinant
protein expression with tetracycline (2 lgÆmL
)1, 24 h).
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